Red Flags Detected
- Delisting (new) — Company received formal Nasdaq deficiency notice for failing to maintain minimum $1.00 bid price requirement for 30 consecutive days.
Humacyte receives Nasdaq delisting warning for stock price below $1.00
Filed May 8, 2026 · Period ending May 4, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified Humacyte on May 4 that its stock closed below the required $1.00 minimum bid price for 30 consecutive business days, violating listing rules.
Item 3.01 verify on EDGAR → -
high
Company has until November 2, 2026 (180 days) to regain compliance by maintaining a closing bid price of $1.00 or higher for at least 10 consecutive business days.
Item 3.01 verify on EDGAR → -
high
Management acknowledged no assurance exists that the company will successfully regain compliance within the deadline, though it will monitor the stock price and consider available options.
Item 3.01 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SMID 10-Q) is open in full — no account needed.
Partner
Trade HUMAW commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 10, 2026 10:44 PM